Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.59 |
| ▸ | NPY1R | P25929 | 8/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.59 |
| ▸ | NPY2R | P49146 | 4/20 | 0.59 |
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433249 | 0.96 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29979938 | 0.92 | TFPI (0.61) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL31676913 | 0.91 | VIPR1 (0.63) | TFPIVIPR2VIPR1 | |
| SCHEMBL31676914 | 0.91 | VIPR1 (0.63) | TFPIVIPR2VIPR1 | |
| SCHEMBL31433273 | 0.90 | BACE1 (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29531034 | 0.89 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30512630 | 0.89 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29979398 | 0.88 | TFPI (0.59) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30567795 | 0.88 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2RVIPR2 | |
| SCHEMBL29530945 | 0.88 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NPY4R 1616/4885NPY1R 2353/4885NPY5R 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.